Citigroup
NBIX icon

Citigroup’s Neurocrine Biosciences NBIX Stock Holding History

Citigroup’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.8M Buy
112,442
+9,169
+9% +$1.22M 0.01% 1241
2025
Q4 		$14.6M Sell
103,273
-133,809
-56% -$19.4M 0.01% 1284
2025
Q3 		$33.3M Sell
237,082
-84,982
-26% -$11.5M 0.01% 802
2025
Q2 		$40.5M Sell
322,064
-144,125
-31% -$16.5M 0.02% 663
2025
Q1 		$51.6M Buy
466,189
+301,009
+182% +$38.1M 0.03% 544
2024
Q4 		$22.5M Sell
165,180
-35,339
-18% -$4.37M 0.01% 891
2024
Q3 		$23.1M Buy
200,519
+84,230
+72% +$11.5M 0.01% 876
2024
Q2 		$16M Sell
116,289
-38,789
-25% -$5.32M 0.01% 994
2024
Q1 		$21.4M Sell
155,078
-16,855
-10% -$2.3M 0.01% 848
2023
Q4 		$22.7M Sell
171,933
-17,915
-9% -$2.06M 0.02% 788
2023
Q3 		$21.4M Sell
189,848
-19,273
-9% -$2.03M 0.02% 747
2023
Q2 		$19.7M Sell
209,121
-9,666
-4% -$944K 0.01% 822
2023
Q1 		$22.1M Buy
218,787
+80,811
+59% +$8.41M 0.02% 790
2022
Q4 		$16.5M Buy
137,976
+2,390
+2% +$280K 0.01% 882
2022
Q3 		$14.4M Buy
135,586
+40,677
+43% +$4.13M 0.01% 960
2022
Q2 		$9.25M Buy
94,909
+33,104
+54% +$3.06M 0.01% 1194
2022
Q1 		$5.79M Sell
61,805
-44,956
-42% -$3.81M ﹤0.01% 1584
2021
Q4 		$9.09M Buy
106,761
+43,336
+68% +$3.99M ﹤0.01% 1437
2021
Q3 		$6.08M Sell
63,425
-39,776
-39% -$3.76M ﹤0.01% 1681
2021
Q2 		$10M Sell
103,201
-6,576
-6% -$630K 0.01% 1417
2021
Q1 		$10.7M Buy
109,777
+2,753
+3% +$289K 0.01% 1333
2020
Q4 		$10.3M Buy
107,024
+20,450
+24% +$1.98M 0.01% 1531
2020
Q3 		$8.33M Buy
86,574
+4,947
+6% +$572K 0.01% 1518
2020
Q2 		$9.96M Buy
81,627
+17,385
+27% +$1.92M 0.01% 1293
2020
Q1 		$5.56M Buy
64,242
+22,141
+53% +$2.17M 0.01% 1572
2019
Q4 		$4.53M Sell
42,101
-12,049
-22% -$1.26M ﹤0.01% 2112
2019
Q3 		$4.88M Sell
54,150
-29,154
-35% -$2.72M ﹤0.01% 1971
2019
Q2 		$7.03M Buy
83,304
+39,178
+89% +$3.22M 0.01% 1677
2019
Q1 		$3.89M Sell
44,126
-24,723
-36% -$2.07M ﹤0.01% 2008
2018
Q4 		$4.92M Buy
68,849
+40,511
+143% +$3.88M 0.01% 1828
2018
Q3 		$3.48M Sell
28,338
-8,985
-24% -$1.02M ﹤0.01% 2200
2018
Q2 		$3.67M Buy
37,323
+17,325
+87% +$1.55M ﹤0.01% 2128
2018
Q1 		$1.66M Buy
19,998
+486
+2% +$41K ﹤0.01% 2777
2017
Q4 		$1.51M Sell
19,512
-20,673
-51% -$1.41M ﹤0.01% 2934
2017
Q3 		$2.46M Buy
40,185
+7,468
+23% +$394K ﹤0.01% 2435
2017
Q2 		$1.5M Sell
32,717
-21,378
-40% -$1.04M ﹤0.01% 2884
2017
Q1 		$2.34M Sell
54,095
-113,758
-68% -$4.87M ﹤0.01% 2325
2016
Q4 		$6.5M Buy
167,853
+145,527
+652% +$6.59M 0.01% 1555
2016
Q3 		$1.13M Buy
22,326
+5,971
+37% +$297K ﹤0.01% 3087
2016
Q2 		$744K Sell
16,355
-68,548
-81% -$3.16M ﹤0.01% 3233
2016
Q1 		$3.36M Buy
84,903
+58,428
+221% +$2.32M ﹤0.01% 1932
2015
Q4 		$1.5M Buy
26,475
+8,449
+47% +$429K ﹤0.01% 2723
2015
Q3 		$717K Buy
18,026
+2,336
+15% +$113K ﹤0.01% 3398
2015
Q2 		$750K Sell
15,690
-2,120
-12% -$89.9K ﹤0.01% 3354
2015
Q1 		$707K Sell
17,810
-11,110
-38% -$397K ﹤0.01% 3414
2014
Q4 		$646K Buy
28,920
+25,678
+792% +$487K ﹤0.01% 3609
2014
Q3 		$50K Sell
3,242
-83
-2% -$1.24K ﹤0.01% 5306
2014
Q2 		$50K Sell
3,325
-15,221
-82% -$215K ﹤0.01% 5173
2014
Q1 		$298K Sell
18,546
-12,427
-40% -$213K ﹤0.01% 3953
2013
Q4 		$289K Buy
30,973
+14,077
+83% +$137K ﹤0.01% 4311
2013
Q3 		$191K Buy
16,896
+10,206
+153% +$140K ﹤0.01% 4198
2013
Q2 		$89K Buy
+6,690
New +$82.2K ﹤0.01% 4953

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's NBIX Position: Q1 2026 in Review

Citigroup increased its Neurocrine Biosciences (NBIX) stake by 8.9% in Q1 2026, buying an estimated $1.22M and bringing the position to 112,442 shares worth $14.8M. The position accounts for 0.01% of the portfolio, ranked #1241.

Citigroup first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $51.6M in Q1 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Citigroup held 112,442 shares of Neurocrine Biosciences worth $14.8M as of Q1 2026.
  • Citigroup bought 9,169 Neurocrine Biosciences shares in Q1 2026, an estimated $1.22M.
  • Neurocrine Biosciences made up 0.01% of Citigroup's portfolio in Q1 2026, its #1241 holding.
  • Citigroup first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Neurocrine Biosciences position peaked at $51.6M in Q1 2025.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.